title: Seizure and cognitive outcomes in children and adolescents with epilepsy treated with topiramate.
abstract: This 12-week open label study explored cognitive and seizure outcomes of 53 children treated with topiramate (TPM). The digit symbol test and verbal learning memory test were administered at baseline and study endpoint. Topiramate was started either in monotherapy or add-on therapy. Overall, 57% of children experienced a ≥50% seizure reduction, 36% became seizure free and cognitive testing revealed no significant changes during TPM therapy. Due to the heterogeneity of the study population, post hoc analyses were added to compare patients in initial or conversion to TPM monotherapy as well as patients who continued add-on therapy. Verbal learning memory test parameters showed neither significant differences within any subgroup comparing baseline with endpoint nor significant differences between described subgroups except for one finding. The digit symbol test revealed no differences between each subgroup between baseline and endpoint. Comparing pre-post differences, TPM monotherapy was associated with better cognitive outcomes than treatment in add-on therapy. These results have to be interpreted with caution given the short study duration and the heterogeneity of the study population. Despite these limitations, our overall results suggest that treatment with topiramate is associated with improved seizure control without significant changes in cognitive functions at the low doses tested.
authors.affiliation: Department of Neuropediatrics, University Hospital, Jena, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Brandl
authors.forename: G
authors.initials: G
authors.lastname: Kurlemann
authors.forename: B
authors.initials: B
authors.lastname: Neubauer
authors.forename: K
authors.initials: K
authors.lastname: Rettig
authors.forename: Barbara
authors.initials: B
authors.lastname: Schäuble
authors.forename: A
authors.initials: A
authors.lastname: Schreiner
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002648:Child; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy / Q000209:etiology; D009483:Neuropsychological Tests; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012640:Seizures / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013997:Time Factors; D000077236:Topiramate; D014706:Verbal Learning / Q000187:drug effects
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose